Figures
Abstract
Background
3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole (DIC) is a five-membered heterocyclic compound containing a N-O bond. The anti-inflammatory effects of this compound were studied both in vitro and in vivo.
Principal Findings
DIC effectively decreased TNF-α and IL-6 release from LPS-stimulated macrophages in a dose dependent manner. DIC diminished the levels of COX-2 with subsequent inhibition of PGE2 production. DIC also compromised HMGB1 translocation from the nucleus to the cytoplasm. Moreover, DIC prevented the nuclear translocation of NF-κB and inhibited the MAPK pathway. In vivo, DIC inhibited migration of neutrophils to the peritoneal cavity of mice.
Citation: Vicentino ARR, Carneiro VC, Amarante AdM, Benjamim CF, de Aguiar AP, Fantappié MR (2012) Evaluation of 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole as a Novel Anti-Inflammatory Drug Candidate. PLoS ONE 7(6): e39104. https://doi.org/10.1371/journal.pone.0039104
Editor: Joao B. Calixto, Universidad Federal de Santa Catarina, Brazil
Received: October 20, 2011; Accepted: May 16, 2012; Published: June 18, 2012
Copyright: © 2012 Vicentino et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro and Conselho Nacional de Desenvolvimento Científico e Tecnológico. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Cytokine regulation represents a potentially important therapeutic target in the inflammatory diseases. A variety of anti-cytokine strategies are being explored for the treatment of inflammation disorders. These include the neutralization of cytokines by soluble receptors or monoclonal antibodies and the activation of anti-inflammatory pathways by bioengineered [1]. However, the anti-cytokine drugs available to date are proteins, and suffer to a varying degree from the general disadvantages associated with protein drugs: limited stability, cellular penetration, cellular activity and oral absorption as well short half-life, rapid metabolism, immunogenicity and high costs of manufacturing. Therefore, small molecular anti-cytokine drugs, which target specific signaling and/or biosynthetic pathways of pro-inflammatory cytokines, would offer an attractive alternative to the treatment of inflammatory diseases [2].
A key element in this pathway is Mitogen-Activated Protein Kinase (MAPK) and nuclear factor kB (NF-κB). Activation of MAPK under a variety of stress stimuli like lipopolysaccharide (LPS) results in the phosphorylation and activation of other kinases and transcription factors such as NF-κB, which is responsible for the transcriptional regulation of genes that encode inflammatory cytokines. For example, the inhibition of these pathways blocks the production of cytokines such as TNF-α, at the transcriptional and translational levels [3]. Importantly, inhibition of the NF-κB pathway also culminates with the transcriptional inhibition of a novel and key cytokine, the High Mobility Group B1 (HMGB1) [4]. HMGB1 is a non-histone chromatin-associated protein that stabilizes DNA structure and modulates transcriptional activity. HMGB1 has been recognized as a potent pro-inflammatory cytokine actively secreted by innate immune cells in response to pathogenic products and released by injured or dying cells. Thus, HMGB1 occupies now a central role in the pathogenesis of both sterile and infectious inflammation [5]–[6].
An initial series of pyridyl-imidazole anti-inflammatory agents served as tools to elucidate the regulation of cytokine production in inflammation. The compound SB-203580, containing a pyridinyl imidazole group, is a practical example of small molecular anti-cytokine agents that inhibited the p38 MAPK and, consequently, decreased cytokine production [7]. Several others inhibitors unrelated to pyridinyl imidazole-based p38 inhibitors were discovered including triazanapthalenones, N,N′-diaryl ureas, N,N-diaryl ureas, benzophenones, pyrazole ketones, indole amides, diamides, quinazolinones, pyrimido[4,5-d]pyrimidinones and pyridylamino-quinazolines. It is of interest to note that a chemically diverse set of compounds inhibits p38 MAPK potently [8].
In a continuous effort to develop improved p38 MAPK inhibitors, Laufer et al synthesized compounds with isoxazole rings by bioisosteric replacement of the imidazole ring of SB-203580 aiming at diminishing its hepatotoxic effect. The compound 4-[3-(4-fluorophenyl)isoxazol-4-yl]pyridine displayed a promising anti-inflammatory activity, by suppressing cytokine release, lowering the affinity for cytochorme P450 and showing a decreased in the IC50 toward isolated p38 MAPK [9]. Another heterocycle with a potential to serve as an anti-inflammatory molecule is the 4,5-dihydroisoxazole, or isoxazoline. The compound VGX-1027 [(S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid] was the first of a new class of immune modulators accepted by the FDA (US Food and Drug Administration) that inhibits the production of pro-inflammatory cytokines by down-regulating the NF-κB and p38 MAPK pathways and up-regulating the ERK pathway [10].
The present work aimed at evaluating the anti-inflammatory potential of 4,5-dihydroisosaxoles, and thus we investigated the immunomodulatory effect of a synthetic 5-(4-pyridyl)-4,5-dihydroisosaxole derivative.
Materials and Methods
Ethics Statement
Animals were handled in strict accordance with good animal practice as defined by Animals Use Ethics Committee of UFRJ (Universidade Federal do Rio de Janeiro), with approval DFBCICB028. The study was conducted adhering to the institutiońs guidelines for animal husbandry.
Synthesis of 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole
The 3-chloro-phenyl-aldoxime was synthesized from 20 mmol of the respective aldehyde and 60 mmol of NH2OH.HCl contained in 20 mL of solvent. The reaction medium was irradiated by microwave radiation for 30 min with potency of 160 W. In the following, the aldoxime reacted with trichloroisocyanuric acid (10 mmol) and triethylamine (20 mmol) for 24 h under stirring at room temperature to produce the corresponding hydroximoyl chlorides. Finally, 30 mmol of 4-vinylpiridine was added to the solution of dichloromethane and hydroximoyl chlorides. This reaction was under stirring for 24 h at 27°C. Soon after, the compound was separated by flash column chromatography, using as eluent hexane and ethyl acetate mixture in proportions of 3∶1, respectively. A yellow powder in 46% yield, mp 92°C was obtained. IR spectrum, cm−1: 1595 (νC=N of 4,5-dihydroisoxazole); 1555 (νC=C); 1078 (νCsp2–Cl). 1H NMR spectrum, δ, ppm, CDCl3: 3.28 (1H, dd, 2JH-H =16.6 Hz, 3JH-H =7.4 Hz); 3.84 (1H, dd, 2JH-H =16.6 Hz, 3JH-H =11.3 Hz); 5.76 (1H, dd, 3JH5-H4b =11.3 Hz, 3JH5-H4a =7.4 Hz); 7.35 (4H, m); 8.62 (2H, d, 3JH-H =6.0 Hz); 7.66 (1H, s); 7.56 (1H, d). 13C NMR spectrum, δ, ppm, CDCl3: 155.1; 42.8; 80.9; 149.8; 120.5; 150.3; 130.7; 130.5; 134.9; 126.9; 124,9; 130,2. Mass spectrum, [M+]: 258. Calcd for C14H11N2OCl: C, 65.0; H, 4.3; N, 10.8. Found: C, 64.7; H, 4.4; N, 10.8.
Cell Culture and Viability
RAW 264.7 macrophage cell line (ATCC - TIB-71™) was grown at 37°C in RPMI 1640 (Sigma) medium supplemented with 10% Fetal Bovine Serum (FBS -Sigma) in a humidified atmosphere of 5% CO2. RAW 264.7 cells were plated at a density of 105 cells/well in 96-well plates. The cells were treated with various concentrations of DIC for 24 h. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT colorimetric assay - Sigma) and the lactate dehydrogenase (LDH) leakage quantified by the CytoTox 96® kit (Promega) according to the manufacturer’s instructions.
TNF-α, IL-6, and PGE2 Quantification
RAW 264.7 cells were pretreated with DIC at the indicated concentrations for 2 h and then stimulated with LPS (SIGMA − 100 ng/mL or 1 µg/mL) for 4 h to detected TNF-α levels or 24 h to IL-6 and PGE2. The levels of TNF-α, and IL-6 in the culture media were quantified using ELISA kits (Peprotech) according to manufacturer’s protocol. The levels of PGE2 in the culture supernatants were quantified using EIA kits (Cayman) according to manufacturer’s protocol.
RAW 264.7 macrophages were treated with DIC (from 10 µM to 500 µM) for 24 h. Cell viabilities were determined by LDH release (A) and MTT assay (B). Values represent means ± SD of three independent experiments. * Significant differences (p>0.05) between treated and untreated cells (250–500 µM), using unpaired t-test.
Western Blot Analysis
RAW 264.7 cells (2×106 cells/well in 6-well plates) were washed twice with cold PBS and harvested by scraping. The pellet was resuspended in extraction lysis buffer (200 mM HEPES/KOH, pH 7.9, 0.35 M NaCl, 20% (v/v) glycerol, 1% (v/v) Nonidet P-40, 1 mM MgCl2, 0.5 mM EDTA, 1 mM PMSF, 0.5 mM Na orthovanadate, 5 µg/mL aprotinin) and incubated on ice for 30 min. Cells were centrifuged at 14,000 rcf at 4°C for 10 min to pellet the cellular debris, followed by a quick freeze of the supernatants. Protein concentration was determined using the Bio-Rad protein assay reagent according to the manufacture’s instruction. Protein extract (30 µg) of treated or untreated cells was electroblotted onto a nitrocellulose membrane following separation on a 15% SDS–polyacrylamide gel electrophoresis. The immunoblot was incubated for 2 h with blocking solution (5% skim milk in TBS) at room temperature, followed by overnight incubation with various dilutions of the primary antibody (COX-2, p38, α-tubulin, phosphor-ERK and ERK, from Santa Cruz; phosphor-p38, phosphor-JNK, JNK and β-actin, from Cell Signaling). The blots were washed three times with Tween-20 0.05%/Tris-buffered saline (T-TBS) and incubated with peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots were again washed three times with T-TBS, and the proteins visualized by enhanced chemiluminescence according to the instructions of the manufacturer (Amersham Life Science).
A and B, following pretreatment with Polymyxin B (Pol B, 15 µg/mL), vehicle (DMSO 0.25%) or DIC (10−200 µM) for 2 h, the cells were treated with LPS (100 ng/mL) for 4 h (A) or 24 h (B). Negative control (CTRL −): cell medium only; Positive control (CTRL +): cells stimulated with LPS, only. TNF-α and IL-6 levels were assayed by ELISA. Values represent means ± SD of three independent experiments. NS, non-significant vs CTRL +; * p<0.05 vs vehicle; ** non-significant vs vehicle. Significances between treated groups were determined using unpaired t-test.
Nuclear Extraction and Electrophoretic Mobility Shift Assay (EMSA)
RAW 264.7 cells were plated at a density of 2×106 cells/well in 6-well plates, pretreated with DIC (150 and 200 µM) for 2 h, and then stimulated with LPS (1 µg/mL) for 1 h. The cells were washed once with PBS, scraped into 1 mL of cold PBS, and pelleted by centrifugation. Nuclear extracts were prepared as described previously by Holden [11]. Cell pellets were resuspended in buffer I (10 mM Tris–HCl pH 7.5, 0.15 M NaCl, 1.5 mM MgCl2, 0.65% NP-40, 0.5 mM PMSF, 10 mM DTT) mixed by vortex and left on ice for 15 min. Cells were centrifuged at 4°C, 12,000 rcf, 2 min and the resultant pellet lysed in buffer II (20 mM Hepes pH 7.9, 25% glycerol, 0.4 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA pH 8.0, 0.5 mM PMSF, 10 mM DTT), left on ice for 2 h, centrifuged at 4°C, 12,000 rcf, 10 min and the supernatant transferred to a new tube. Nuclear extracts (10 µg) were mixed with 200 c.p.m. of double-stranded 32P-end-labled-NF-κB oligonucleotide: 5′-AGTTGAGGGGACT-TTCCCAGGC-3′ (underline indicates the κB consensus sequence or a binding site for NF-κB/cRel homodimeric or heterodimeric complex). Binding reactions were carried out at 37°C for 30 min in 30 µL of binding buffer containing 10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 4% glycerol, 1 µg of poly (dI-dC), and 1 mM DTT. DNA–protein complexes were separated from the unbound DNA probe on a native 6% polyacrylamide gels, run at 200 V in 0.5×Tris Boric Acid EDTA (TBE) buffer. Gels were vacuum-dried for 1 h at 80 °C and exposed to X-ray film at −70°C overnight.
RAW 264.7 macrophages were pretreated with DIC 200 µM for 2 h prior to addition of LPS (1 µg/mL) for 24 h. Intracellular HMGB1 was visualized with green immunofluorescent FITC-staining. Untreated cells (UT); LPS-stimulated cells (LPS); DIC-treated cells stimulated with LPS (LPS + DIC).
Immunocytochemistry
The immunocytochemistry approach was used to investigate the immunolocalization of HMGB1 and p65. RAW 264.7 cells were plated on glass coverslips in 24-well plates (50,000 cells/well) and cultured in RPMI 1640 medium supplemented with 10% FBS, under standard culture conditions of 5% CO2. The cells were pretreated with 200 µM of DIC or vehicle (DMSO 0.25%) for 2 h and then stimulated with LPS (1 µg/mL) for 24 h, for HMGB1 analysis or 1 h, for p65 analysis. For immunofluorescence detection of proteins, cells were fixed in 4% paraformaldehyde (Sigma) for 10 min and then, blocked for 1 h in 5% Bovine Serum Albumin (BSA – Sigma) diluted in Tween-20 0.5%/Phosphate-buffered saline (T-PBS) followed by permeabilization in PBS containing 10% of Triton X-100 for 30 min. Glass coverslips were incubated with monoclonal primary antibodies (HMGB1, Abcam; p65, Cell Signaling) overnight at 4 °C. After washing, an Alexa Fluor 488 (FITC-staining) conjugated anti-rabbit antibody (Invitrogen) was added for 1 h at room temperature. An irrelevant anti-IgG1 and secondary antibodies only were used as negative controls (data not shown). The chamber slides were mounted in Prolong Gold antifade reagent with DAPI (Invitrogen). Fluorescence images were obtained with a Zeiss Axio Observer.Z1 invert microscope equipped with 1006× objective lens and an AxioCam MRm camera, in the ApoTome mode.
Thioglycollate-Induced Peritonitis in Mice
These experiments were performed according to the method described by Savill [12]. Female Balb/c, 8 weeks old (CECAL, FIOCRUZ, Rio de Janeiro) were treated intraperitoneally (i.p.) with DIC (5 mg/kg) or vehicle (DMSO 2.4%), 30 min before the administration of 1 mL of 3% thioglycollate (Difco-BD Biosciences). After 4 h, animals were killed by cervical dislocation and the peritoneal cavity was washed with 3 mL of cold PBS. The peritoneal exudates were retrieved and their volume was measured. Total cell migration was counted using a Neubauer chamber. Exudates (100 µL) were mounted on glass slides by cytospinning for 10 min at 1,000 rcf (Cytospin 3, Shandon Scientific) and stained with hematoxilin-eosin for differential cell count. Two hundred cells per sample were counted.
(A) RAW 264.7 macrophages were pretreated with DIC 200 µM for 2 h prior to addition of LPS (1 µg/mL) for 24 h and then PGE2 levels were determined by EIA. The values shown are means ± SD of three independent experiments. NS, non-significant vs CTRL+; * p<0.05 vs vehicle; ** non-significant vs vehicle. Significances between treated groups were determined using unpaired t-test. (B) Protein levels of COX-2 were determined by western blot analysis of cellular protein extract (upper panel). A representative immunoblot out of three independent experiments were shown.
Statistical Analysis
Results were expressed as the mean ± S.D. of triplicate experiments. Statistically significant values were compared using t-test, and p values of less than 0.05 were considered statistically significant. GraphPad Prism 5.0 statistical software (NIH software) was used.
RAW 264.7 macrophages were pretreated with 200 µM of DIC for 2 h prior to addition of LPS (1 µg/mL) for 15 min, and then the whole cell lysate was analyzed by western blot using antibodies against the phosphorylated (activated) and unphosphorylated MAPK. The data shown are representative of three independent experiments.
Results
Synthesis of 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole
The compound 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole, or DIC (Figure 1) was synthesized from a cycloaddition reaction of 3-chloro-benzonitrile oxide to 4-vinylpiridine [13]. As a result of this reaction, a yellow powder (46% yield) was obtained. DIC, which is a five-membered heterocyclic compound containing a N-O bond was characterized by FTIR, mass spectroscopy and 1H-NMR and 13C-NMR, as described in the materials and methods section.
(A) RAW 264.7 macrophages were grown on coverslips, pretreated with DIC at a concentration of 200 µM for 2 h and stimulated with LPS (1 µg/mL) for 1 h. FITC-immunostained for NF-κB/p65 viewed under a fluorescence microscope in the ApoTome mode. Untreated cells (NT); LPS-stimulated cells (LPS); DIC-treated cells stimulated with LPS (LPS + DIC). Scale bar: 10 µm. (B) EMSA analysis: nuclear extracts were prepared from unstimulated cells (lane 2); cells stimulated with LPS (1 µg/mL - lane 3); cells pretreated with Polymyxin B (15 µg/mL - lane 4), cells treated with vehicle only (DMSO 0.25% - lane 5); cells treated with increasing concentrations of DIC (lanes 6 and 7) for 2 h and stimulated with LPS for 1 h. The analysis was based on the DNA binding by the active NF-ΚB heterodimer p50–p65. DNA binding inhibition of the p50–p65 heterodimers by DIC is observed (compare lanes 3 and 5 with lanes 6 and 7; the intensities of the upper bands [p50–p65 arrow] in lanes 6 and 7 are significantly lower).
Effect of DIC on Macrophage Toxicity
Two different cytotoxicity tests (LDH and MTT) were used to evaluate the biocompatibility of DIC. The LDH test measures only severe cell damage and enzyme release upon damage, whereas the MTT test measures the mitochondrial activity of the cells [14].
In vitro cytotoxicity was determined in RAW 264.7 macrophages treated with DIC for 24 h at concentrations ranging from 10 to 500 µM. Concentrations of DIC up to 200 µM did not display any cellular toxicity against the cells (measured by both methods, LDH or MTT). Alternatively, higher concentrations of DIC (from 250 µM to 500 µM) were toxic to the cells (Figure 2 A and B).
(A) DIC (5 mg/kg) or vehicle (DMSO 2.4%) was administered intraperitoneally 30 min before the thioglycollate administration. Mice were sacrificed after 4 h of thioglycollate-induced peritonitis. Total cell migration was counted using a Neubauer chamber. (B) Differential cell count was evaluated by Cytospin. Data represent mean ± S.D. from at least 8 animals per group. * P<0.05 (significances between treated groups were determined using unparied t-test).
Effect of DIC on LPS-induced TNF-α and IL-6 Production
To determine the effect of DIC on the production of pro-inflammatory cytokines following LPS treatment, ELISAs were performed using cell culture supernatants. During incubation, cells in the resting state produced undetectable levels of TNF-α, but 81.5 pg/mL of IL-6. When the cells were exposed to LPS, TNF-α production increased about 3.000 fold (2.700 pg/mL) and IL-6 increased about 100 fold (8.300 pg/mL) over the basal level (Figure 3 A and B). It is important to note that DIC inhibited the production of both cytokines from concentrations ranging from 50 to 200 µM (Figure 3 A and B). However, DIC at 200 µM concentration was able to almost completely abolish the production of TNF-α and IL-6 to 89.4% and 94.9%, respectively (Figure 3 A and B). DMSO at 0.25% and Polymyxin B (15 µg/mL) were used as controls.
Inhibition of LPS-induced Nuclear Translocation of HMGB1 by DIC
Besides its canonical DNA transactions within the nucleus, HMGB1 was recently recognized as an inflammatory mediator actively secreted as a cytokine by macrophages and other inflammatory cells upon cell injury and infection [5], [15].
Since we showed that DIC inhibited the release of classical cytokines such as TNF-α and IL-6 (Figure 3 A and B), we decided to investigate whether DIC could also interferer in the secretion of HMGB1 by LPS-activated macrophages. Immunofluorescence microscopy showed that HMGB1 remained in the nuclei of macrophages when the cells received no inflammatory (LPS) stimulus (Figure 4, upper panels, or UT). However, HMGB1 was readily translocated from the nucleus to the cytoplasm of macrophages that were stimulated with LPS (Figure 4, central panels, or LPS). Importantly, when macrophages were stimulated by LPS and treated with DIC, we clearly observed the retention of HMGB1 in the nuclei of the cells (Figure 4, bottom panels, or LPS + DIC).
Effect of DIC on LPS-induced PGE2 Production
To investigate the effect of DIC on LPS-induced PGE2 production by RAW 264.7 macrophages, cell culture media were harvested, and the levels of PGE2 were measured after exposure of LPS for 24 h. The treatment with DIC (10 to 200 µM) significantly inhibited LPS-induced PGE2 production, corresponding to 75.6% at 200 µM (Figure 5A).
Since DIC was found to inhibit PGE2 production, we decided to investigate whether this inhibitory effect was related to the regulation of COX-2 expression. Western blot analysis showed that COX-2 protein levels were markedly up-regulated in response to LPS for 24 h (Figure 5B, upper panel, lane 2). Importantly, DIC significantly inhibited the expression of COX-2 (lanes 5 and 6). DIC has no effect on the expression of α-tubulin (Figure 5B, bottom panel).
In addition, LPS leads to COX-2 activation, which in turn leads to the production of PGE2 (Figure 5A, CTRL+); we see that in the presence of Pol B, only 10% (measured by densitometry) of COX-2 was inhibited (Figure 5B, lane 3); thus, we believe that the 35% reduction in PGE2 release by Pol B is reflected by the slight reduction in COX-2 expression.
Inhibition of LPS-induced MAPK Activation by DIC
MAPKs play critical roles in the regulations of cell growth and differentiation and in the cellular responses to cytokines and other stresses. In addition, MAPKs are also known to be important for the transcriptional activation of NF-κB [16]. To investigate whether the inhibition of the inflammatory response by DIC was mediated by the MAPK pathway, we examined the effect of DIC on the LPS-stimulated phosphorylation of p38 MAPK, ERK1/2 and JNK in RAW 264.7 cells. Western blot analysis showed that DIC was able to inhibit p38, ERK and JNK phosphorylation (Figure 6, compare: lanes 2 and 6 for pp38; lanes 2, 5 and 6 for pERK; lanes 2, 5 and 6 for pJNK). Constitutive levels of p38, ERK and JNK are shown (p38, ERK and JNK panels). The expression levels of actin remained unaltered after the treatments (Figure 6, bottom panel).
Effect of DIC on the Activation of NF-κB Signaling Pathway
By employing immunofluorescence microscopy, we found that p65 was localized to the cytoplasm of macrophages before LPS stimulation (Figure 7A, upper panels, or UT). However, 1 h after stimulation with LPS at 1 µg/mL, the majority of intracellular p65 translocated from the cytoplasm to the nucleus, demonstrated by strong p65 staining within the nucleus (Figure 7A, central panels, or LPS). When macrophages were stimulated with LPS and treated with 200 µM of DIC, LPS-induced nuclear translocation of p65 was strongly inhibited, as shown by the lack of p65 staining within the nuclei of the cells (Figure 7A, bottom panels, or LPS + DIC). To further examine the effect of DIC on LPS-induced NF-κB translocation, we performed EMSA using an oligonucleotide probe containing a NF-κB response element. We showed that treatment of macrophages with LPS alone led to an increase in NF-κB-(p50–p65)-DNA binding activity (Figure 7B, lane 3). As expected, pretreatment with Polymyxin B (a scavenger of LPS) was able to attenuate NF-κB binding (Figure 6B, lane 4), and DMSO had no effect in DNA binding (Figure 7B, lane 5). However, pretreatment with DIC prior LPS stimulation significantly inhibited NF-κB-(p50–p65)-DNA binding activity (Figure 7B, lanes 6 and 7).
Effect of DIC on Cell Migration in Thioglycollate-induced Peritonitis in Mice
To explore the anti-inflammatory effect of DIC in vivo we first studied cell recruitment in the peritoneal cavity of mice. The animals were pretreated with DIC (5 mg/kg) or vehicle (DMSO 2.4%) i.p. and 30 min later the thioglycollate was injected i.p. to induce peritonitis. Similar to previous data [17], 4 h after thioglycollate injection, we found an increase of inflammatory cells (Figure 8A), mainly consisting of neutrophils (81%), as shown in Figure 8B. In the control group without thioglycollate injection, only resident macrophages were found in the peritoneal cavity (Figure 8B, first column). Pretreatment with DIC followed by thioglycollate injection decreased the recruitment of neutrophils (56.5% of inhibition when compared with the thioglycollate group) as shown in Figure 8 A and B, third column.
Discussion
Pro-inflammatory mediators such as cytokines are strictly related to immuno-pathogenic processes of a variety of inflammatory diseases. These evidences triggered the development of a new strategy for the treatment of immune-inflammatory disorders, based on the neutralization of the action of pathogenic cytokines. Such neutralization may act through the use of monoclonal antibodies or soluble receptors. However, this type of therapy still shows disadvantages due to the fact that the administration is based on protein molecules [2].
In this regard, there is a growing need for the development of synthetic small molecular anti-cytokine agents. Today, the MAPK and NF-κB pathways are important targets for these drugs, since they have seen to be over activated in a variety of inflammatory diseases, culminating in the over expression of cytokines [3].
With the goal of generating small molecular anti-cytokine agents that could mediate inflammatory responses, in this work we characterized the anti-inflammatory activity of a synthetic 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole, or DIC, a five-membered heterocyclic compound containing a N-O bond. The 4,5-dihydroisoxazoles are easily synthesized through a cycloaddition reaction [13], [18]–[19]. This reaction produce different 4,5-dihydroisoxazoles disubstituted which can present different bioactivities as antifungal, anticancer, antibacterial, antiparasitic and anti-inflammatory activity [10], [20]–[28]. Although the anti-inflammatory role of the 4,5-dihydroisoxazoles is still not completely understood, it is suggested that the heterocyclic component plays a major role in favoring the ideal location of its substituent in space, in a way that it facilitates and allows chemical interactions between the drug and its biological targets [9], [23]. 4,5-dihydroisoxazol derivatives can present anti-inflammatory activities due to the nature of the substituent [7], [22]–[23]. The literature has reported that derivatives of this heterocyclic compound such as the VGX-1027 [7] present an immunomodulatory activity that inhibits the MAPK/NF-κB signaling pathways. Additionally, this type of activity has been reported for several derivatives containing pyridines as substituent, although the number of papers investigating these derivatives is still limited (see patent at www.wipo.int/patentscope/search/en/wo2005034952).
The present paper reports the characterization of the anti-inflammatory activity of a new derivative of 4,5-dihydroisoxazol containing a phenyl and pyridyl radicals as substituent at positions C3 and C5 of the heterocyclic, respectively.
In the context of the innate immunity, it is known that components of the Gram-negative bacteria wall such as LPS, stimulate macrophages to produce cytokines like TNF-α, IL-1β, IL-6, IL-12, HMGB1, several chemokines, and also induce the synthesis of enzymes as iNOS, COX-2 and others [29]–[30]. These pro-inflammatory mediators and enzymes play key roles in the pathogenesis of several chronic and acute inflammatory diseases. Consequently, the use of synthetic drugs to modulate the production of these mediators becomes an alternative therapeutic strategy [2]. In this regard, we showed in this paper that DIC possesses anti-inflammatory properties by inhibiting the production of TNF-α, IL-6, and PGE2 and in macrophages stimulated with LPS. Moreover, our data also suggested that DIC acts as an anti-inflammatory compound through the inhibition of HMGB1 translocation and subsequent secretion by macrophages.
It is well established that NF-κB is the main transcriptional regulator of a variety of genes involved with immune responses [31]. Another key element to the regulation of cytokine production is the MAPKs, which are strictly related with the activation of NF-κB, through the action of MSK1 [16]. Inhibitors of p38 MAPK and NF-κB block the production of IL-1, TNF-α and HMGB1 at the transcriptional and translational levels, being effective in the treatment of chronic inflammatory diseases [3]–[4]. Our data demonstrated that LPS-activated macrophages that were treated with DIC resulted in inhibition of the MAPK pathway, with the subsequent inhibition of the NF-κB pathway. Thus, we showed that treatment of macrophages with DIC inhibited the translocation of p65 from the cytoplasm to the nucleus. In this context, the absence of p65 in the nucleus ultimately compromised the DNA binding function of NF-κB, as confirmed by our EMSA assays. These set of data led us to believe that DIC is somewhat affecting the MAPK/NF-κB signaling pathways.
In this study we described that DIC is not cytotoxic and possesses significant anti-inflammatory activity. It is also important to bear in mind that the obtainment of the synthetic DIC is fast and of low cost. This summarizes the potential value of the 5-(4-pyridyl)-4,5-dihydroisosaxole as a lead compound for the development of a novel anti-inflammatory drug.
Author Contributions
Conceived and designed the experiments: ARRV VCC CFB APA MRF. Performed the experiments: ARRV VCC AMA CFB. Analyzed the data: ARRV VCC AMA CFB APA MRF. Contributed reagents/materials/analysis tools: CFB APA MRF. Wrote the paper: ARRV VCC MRF.
References
- 1. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907–916.
- 2. Wagner G, Laufer S (2006) Small molecular anti-cytokine agents. Med Res Rev 26: 1–62.
- 3. Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717–726.
- 4. Penzo M, Molteni R, Suda T, Samaniego S, Raucci A, et al. (2010) Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol 184: 4497–4509.
- 5. Andersson U, Tracey KJ (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29: 139–162.
- 6. Yamada S, Maruyama I (2007) HMGB1, a novel inflammatory cytokine. Clin Chim Acta 375: 36–42.
- 7. Gallagher TF, Seibel GL, Kassis S, Laydon JT, Blumenthal MJ, et al. (1997) Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 5: 49–64.
- 8. Cirillo PF, Pargellis C, Regan J (2002) The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr Top Med Chem 2: 1021–1035.
- 9. Laufer SA, Margutti S, Fritz MD (2006) Substituted isoxazoles as potent inhibitors of p38 MAP kinase. ChemMedChem 1: 197–207.
- 10. Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, et al. (2007) In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin Immunol 123: 311–323.
- 11. Holden NS, Tacon CE (2011) Principles and problems of the electrophoretic mobility shift assay. J Pharmacol Toxicol Methods 63: 7–14.
- 12. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, et al. (1989) Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 83: 865–875.
- 13. Rodrigues RD, de Aguiar, AP (2001) A simple and efficient method for the synthesis of nitrile oxide from aldoxime using trichloroisocyanuric acid. Synthetic Communications 31: 3075–3080.
- 14. Shahnaz G, Perera G, Sakloetsakun D, Rahmat D, Bernkop-Schnurch A (2010) Synthesis, characterization, mucoadhesion and biocompatibility of thiolated carboxymethyl dextran-cysteine conjugate. J Control Release 144: 32–38.
- 15. El Gazzar, M (2007) HMGB1 modulates inflammatory responses in LPS-activated macrophages. Inflamm Res 56: 162–167.
- 16. Vermeulen L, De Wilde, G, Van Damme, P, Vanden Berghe, W Haegeman, G (2003) Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 22: 1313–1324.
- 17. Wan H, Coppens JM, van Helden-Meeuwsen, CG Leenen, PJ, van Rooijen, N, et al, et al. (2009) Chorionic gonadotropin alleviates thioglycollate-induced peritonitis by affecting macrophage function. J Leukoc Biol 86: 361–370.
- 18. Christl M, Huisgen R (1973) 1,3-Dipolar Cycloadditions.74. Orientation Phenomena in Cycloadditions of Aliphatic and Aromatic Nitrile Oxides to Alpha,Beta-Unsaturated Carboxylic Esters. Chemische Berichte-Recueil 106: 3345–3367.
- 19. Xu WM, Huang X, Tang E (2005) Solid-phase synthesis of 1,2-diheterocyclic-substituted (E)-olefins from a supported selenium resin. J Comb Chem 7: 726–733.
- 20. Ahirwar MK, Bardia R, Shrivastava SP (2010) Synthesis and Antifungal Activity of Some 3-[3-(5-Nitro)indolyl]-5-(4-substituted phenyl)isoxazoline and Isothiazoline Derivatives. Asian Journal of Chemistry 22: 7493–7497.
- 21. Amir M, Javed SA, Kumar H (2010) Design and synthesis of 3-[3-(substituted phenyl)-4-piperidin-1-ylmethyl/−4-morpholin-4-ylmethyl-4,5-dihydro-isoxazol-5-yl]-1H-indoles as potent anti-inflammatory agents. Medicinal Chemistry Research 19: 299–310.
- 22. Bhusari KP, Dravyakar BR, Kawade DP, Khedekar PB (2008) Design and syntheses of some new diphenylaminoisoxazolines as potent anti-inflammatory agent. Indian Journal of Chemistry Section B-Organic Chemistry Including Medicinal Chemistry 47: 1559–1567.
- 23. Habeeb AG, Praveen Rao, PN Knaus, EE (2001) Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. J Med Chem 44: 2921–2927.
- 24. Kamal A, Bharathi EV, Reddy JS, Ramaiah MJ, Dastagiri D, et al. (2011) Synthesis and biological evaluation of 3,5-diaryl isoxazoline/isoxazole linked 2, 3-dihydroquinazolinone hybrids as anticancer agents. European Journal of Medicinal Chemistry 46: 691–703.
- 25. Lee RE, Rakesh Sun, D Lee, RB Tangallapally, RP (2009) Synthesis, optimization and structure-activity relationships of 3, 5-disubstituted isoxazolines as new anti-tuberculosis agents. European Journal of Medicinal Chemistry 44: 460–472.
- 26. Ozoe Y, Asahi M, Ozoe F, Nakahira K, Mita T (2009) Antiparasitic isoxazoline: Novel chemistry of ligand-gated chloride channel (LGCC) blockers. Abstracts of Papers of the American Chemical Society 238: 380–380.
- 27. Ozoe Y, Asahi M, Ozoe F, Nakahira K, Mita T (2010) The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels. Biochemical and Biophysical Research Communications 391: 744–749.
- 28. Reddy KRV, Sridhara AM, Keshavayya J, Ambika DMS, Gopinath VS, et al. (2011) Synthesis, Antimicrobial and Cytotoxicity Studies of Some Novel Modified Strobilurin Derivatives. Journal of the Brazilian Chemical Society 22: 849–U859.
- 29. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20: 197–216.
- 30. Kim JY, Shin JS, Ryu JH, Kim SY, Cho YW, et al. (2009) Anti-inflammatory effect of anemarsaponin B isolated from the rhizomes of Anemarrhena asphodeloides in LPS-induced RAW 264.7 macrophages is mediated by negative regulation of the nuclear factor-kappaB and p38 pathways. Food Chem Toxicol 47: 1610–1617.
- 31. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21: 335–376.